Evidence map›Paper›PMID 19039126›Full record

ArticleScience (New York, N.Y.)2008

Microbiology. An antibiotic mimics immunity.

Carl Nathan

Abstract readComment
PubMed Publisher
In one paragraph

Article in Science (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Mycobacterium tuberculosis as teacher.Nature microbiology · 2023
    Article
  2. Review
  3. Kunkel Lecture: Fundamental immunodeficiency and its correction.The Journal of experimental medicine · 2017
    Review
  4. Article
  5. Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  6. Article
  7. Fresh approaches to anti-infective therapies.Science translational medicine · 2012
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Conversion of NO2 to NO by reduced coenzyme F420 protects mycobacteria from nitrosative damage.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Carl NathanDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA. cnathan@med.cornell.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnaerobiosisAntitubercular AgentsGlucosephosphate DehydrogenaseHumansMycobacterium tuberculosisNitric OxideNitroimidazolesNitroreductasesReactive Nitrogen SpeciesRiboflavinTuberculosisAntitubercular Agentscoenzyme F420Glucosephosphate DehydrogenaseNitric OxideNitroimidazolesNitroreductasespretomanidReactive Nitrogen SpeciesRiboflavin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.